Skip to main content
Clinical Trials/NCT05301790
NCT05301790
Not yet recruiting
Not Applicable

Added Value of Breast MRI in Evaluation of Pathologic Response in Patients With Locally Advanced Breast Cancer Who Undergo Neoadjuvent Chemotherapy

Assiut University0 sites45 target enrollmentMay 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Role of MRI in Evaluation of Breast Cancer
Sponsor
Assiut University
Enrollment
45
Primary Endpoint
comparison of MRI findings with pathologic results
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

evaluation of pathological response in breast mass by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results

Detailed Description

evaluation of pathological response in locally advanced breast masses by use of breast MRI in patients receiving neoadjuvent chemotherapy via comparison with pathological results

Registry
clinicaltrials.gov
Start Date
May 2022
End Date
December 2024
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Doaa Maher Ebied Maher

resident

Assiut University

Eligibility Criteria

Inclusion Criteria

  • all women referred to the radiology department for breast MRI examination either for screening, evaluation of suspicious lesions onsono-mammography \\
  • Patients with locally advanced breast cancer
  • Patients with early stage breast cancer and chemo-responsive tumour markers (i.e. triple negative, Her2+), who will benefit from downsizing for breast conserving surgery (BCS)
  • Absolute or Relative contraindications to surgery (advanced age/multiple medical comorbidities) in the setting of estrogen receptor positive tumours (for consideration of neoadjuvant endocrine therapy)3
  • Patients must be elder than 18 years old.
  • patients with accepted renal function

Exclusion Criteria

  • Patients with metastatic breast cancer.
  • Patient with breast mass more than 5 cm .
  • Patients with fungating breast mass .
  • Patients with stage IV \[tumor spread to chest wall and to skin \].
  • pregnant women especially in 1th trimester.
  • Patient with presence of any paramagnetic substance as pacemakers.
  • severely ill patients .
  • patients with claustrophobia.
  • arrhythmic patients

Outcomes

Primary Outcomes

comparison of MRI findings with pathologic results

Time Frame: baseline

added value of breast MRI in evaluation of pathologic response in patients with locally advanced breast cancer who undergo neoadjvent chemotherapy

Similar Trials